TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06725381
Drug: SKB571
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT06726980
Drug: dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 5 % dextrose infusion
Study: NCT06726980
Drug: Dextrose 10%
Normalized name: DEXTROSE 10% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 10 % dextrose infusion (25gm/ 250 mL)
Study: NCT06726980
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive infused IV 0.9 % saline
Study: NCT06726291
Drug: NEPA (300mg netupitant/0.5mg palonosetron)
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Study: NCT06727214
Drug: Chemotherapy with platine
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical records that patients received neoadjuvant systemic chemotherapy platine based
Study: NCT05030168
Drug: Ketosteril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoanalogues of essential amino acid
Study: NCT05488925
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Voltral SR100, 100 mg
Study: NCT05488925
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feldene, 20 mg
Study: NCT00117130
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06101992
Drug: Mesoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
Study: NCT00687180
Drug: Treatment with mycophenolat mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00687180
Drug: Treatment with azathioprin
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05065359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, 0 mg, BID for 14 days
Study: NCT04839016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05217160
Drug: KeraStat® Gel application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes.
Study: NCT06068439
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
Study: NCT06068439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
Study: NCT05732493
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 d1-14 q3w
Study: NCT06268054
Drug: DEH113
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT06268054
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05551858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avicel fiber filled capsule taken by mouth three times daily
Study: NCT06167265
Drug: PMR Tablet 145 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (total daily dose of 290 mg)
Study: NCT05046132
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules via oral administration.
Study: NCT05046132
Drug: SC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via SC injection.
Study: NCT04949633
Drug: Prostaglandins
Normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second cervical ripening lasting a maximum of 24 hours
Study: NCT00004878
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05739903
Drug: DA-1229_01 5/1000mg (After)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05007522
Drug: Ketotifen/Indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablet, 75 mg SR tablet
Study: NCT05007522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT05126004
Drug: N Acetyl L Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Study: NCT04332666
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of NaCl 0.9% without diluted peptide in it
Study: NCT05295940
Drug: LY3841136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05295940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06300489
Drug: irinotecan liposomes+capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD).
Study: NCT06458543
Drug: Longidaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
Study: NCT04663750
Drug: subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
Study: NCT05432713
Drug: LP-168 tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Study: NCT05432713
Drug: LP-168 Placebo tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
Study: NCT04871425
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl
Study: NCT04003805
Drug: Standardized Research E-cigarette (SREC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
Study: NCT00093210
Drug: rFIX
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00093210
Drug: rFIX-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04707313
Drug: Placebo (Cohorts 1 and 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 matching placebo tablets taken twice daily
Study: NCT04707313
Drug: Placebo (Cohort 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 matching placebo tablets taken twice daily
Study: NCT06538558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
Study: NCT05943886
Drug: HEC88473 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Study: NCT05943886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous injection in the abdomen.
Study: NCT05120362
Drug: Cream containing JAK Inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug is a cream containing JAK Inhibitor.
Study: NCT05894486
Drug: Lutetium[177Lu] Oxodotreotide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
Study: NCT06115512
Drug: AGA111
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study: NCT06115512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study: NCT05975983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Study: NCT04913779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
Study: NCT05100199
Drug: OnabotulinumtoxinA X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05576181
Drug: ThisCART19A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
Study: NCT05576181
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT06164327
Drug: BEBT-908 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
Study: NCT04970342
Drug: Placebo (Lactose) Capsule
Normalized name: lactose Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
Study: NCT04996264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
Study: NCT04996264
Drug: Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
Study: NCT05977400
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Gentamicin
Study: NCT05977400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Normal Saline
Study: NCT05874284
Drug: Gelofusin
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
Study: NCT05147376
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
Study: NCT03656029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will smoke a placebo cigarette
Study: NCT06518044
Drug: N Acetyl L Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
Study: NCT05288348
Drug: Sufentanil 30 MCG Sublingual Tablet
Normalized name: SUFentanil 30 MCG Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microgram sublingual tablet administered using sublingual applicator
Study: NCT05288348
Drug: standard care pain treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care pain treatment given in Emergency Department
Study: NCT05951946
Drug: BR3006-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT05951946
Drug: BR3006-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT05951946
Drug: BR3006-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT05297448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Twice Daily
Study: NCT05616468
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study: NCT05677438
Drug: CKD-498 dose#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT05677438
Drug: CKD-498 dose#2
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT05677438
Drug: CKD-498 dose#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT05677438
Drug: Placebo of CKD-498 dose#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT05677438
Drug: Placebo of CKD-498 dose#2
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT05677438
Drug: Placebo of CKD-498 dose#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 24 weeks
Study: NCT04993755
Drug: TPN-101, 400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT04993755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT04752163
Drug: DS-1594b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given DS-1594b PO
Study: NCT04752163
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04752163
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT04752163
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT06079320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablets from Day 1 to Day 5
Study: NCT05222828
Drug: Carbocaine Injectable Product
Normalized name: Carbocaine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection per patient
Study: NCT05373446
Drug: SSD8432 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
Study: NCT05373446
Drug: SSD8432 750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
Study: NCT05373446
Drug: SSD8432Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
Study: NCT04727424
Drug: Fluoxetine 20 MG
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.
Study: NCT04727424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)
Study: NCT05250141
Drug: Levodopa 250mg and Carbidopa 25mg Test Drug tablet
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT05250141
Drug: Levodopa 250mg and Carbidopa 25mg Referent Product tablet
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sinemet (Savio Industrial S.R.L, Brazil)
Study: NCT05664100
Drug: FX-345
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of FX-345
Study: NCT05664100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of placebo
Study: NCT05401227
Drug: Ts-134
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days of TS-134 20 mg
Study: NCT05401227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days of placebo TS-134
Study: NCT05286762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized at Visit 2 to Placebo
Study: NCT01363700
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05153564
Drug: NNC0480-0389 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Study: NCT05153564
Drug: NNC0480-0389 30 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Study: NCT05153564
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Study: NCT05862610
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
Study: NCT05014672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05724472
Drug: rVSV∆G-SEBOV-GP Vaccine or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV∆G-SEBOV-GP Vaccine or Placebo